Verona Pharma Stock Target Price and Analyst Consensus
| VRNA Stock | USD 62.70 1.81 2.81% |
The current analyst and expert consensus on Verona Pharma is Strong Buy, with 5 strong buy opinions. The current projected Verona Pharma target price consensus is 61.00 with 8 analyst opinions. Check out Macroaxis Advice on Verona Pharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. The most common way Verona Pharma PLC analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Verona Pharma executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Verona Pharma. We strongly encourage you to use your own analysis of Verona Pharma PLC to validate this buy or sell advice. Verona Pharma buy-or-sell recommendation module provides average expert sentiment on the projected Verona Pharma PLC target price to derive its highest and lowest estimates based on projected price volatility of 3.7439.
Lowest Forecast 55.51 | Highest Forecast 67.71 | Target Price 61 |
Verona |
It's important to approach Verona Pharma's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Verona Pharma Target Price Consensus
Verona target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Verona Pharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Verona analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Verona stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Verona Pharma PLC, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationVerona Pharma Target Price Projection
Verona Pharma's current and average target prices are 62.70 and 61.00, respectively. The current price of Verona Pharma is the price at which Verona Pharma PLC is currently trading. On the other hand, Verona Pharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Verona Pharma Market Quote on 29th of March 2025
Target Price
Analyst Consensus On Verona Pharma Target Price
Verona Pharma Analyst Ratings
Verona Pharma's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Verona Pharma stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Verona Pharma's financials, market performance, and future outlook by experienced professionals. Verona Pharma's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Verona Pharma price targets
Verona Pharma's stock target price is an estimate of its future price, usually made by analysts. Using Verona Pharma's target price to determine if it is a suitable investment can be done through the following steps:- Look at Verona Pharma's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Verona Pharma's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Verona Pharma Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Verona Pharma is a key component of Verona Pharma valuation and have some predictive power on the future returns of a Verona Pharma.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Cancer Fighters Invested over 90 shares | |
 | Air Invested over 400 shares | |
 | Macroaxis Index Invested over 200 shares | |
 | Plastics Invested over 20 shares | |
 | Precious Metals Invested over 100 shares | |
 | Driverless Cars Invested over 300 shares | |
 | Macroaxis Picks Invested few shares | |
 | Hedge Favorites Invested over 60 shares | |
 | Momentum Invested over 60 shares |
Check out Macroaxis Advice on Verona Pharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Please note, the presentation of Verona Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Verona Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Verona Pharma's management manipulating its earnings.